Please try another search
FunPep Company Limited engages in the research and development of pharmaceuticals drugs, functional cosmetics, and medical devices based on functional peptides. The company is developing SR-0379, a functional peptide for skin ulcer; FPP003, an antibody-inducing peptide that is in Phase II clinical study for the treatment of psoriasis in Australia, as well as phase II clinical trial for ankylosing spondylitis in Japan; and FPP004X, an antibody-inducing peptide for pollinosis. It is also developing FPP006, a corona peptide vaccine; and FPP005, a antibody including peptide for psoriasis. FunPep Company Limited was incorporated in 2013 and is based in Tokyo, Japan.
Name | Age | Since | Title |
---|---|---|---|
Hideki Tomioka | - | 2015 | CSO, Director of R&D, Executive Manager of Clinical Research and Director |
Toshimi Miyoshi | - | 2015 | President, CEO & Director |
Taketoshi Hayashi | - | 2015 | CFO, GM & Director |
Norikazu Eiki | 75 | 2015 | Director |
Naruhito Minami | - | 2022 | Corporate Auditor |
Junya Manabe | 51 | 2022 | Corporate Auditor |
Naruhito Minami | 61 | 2015 | Corporate Auditor |
Motoji Horiguchi | 79 | 2015 | Corporate Auditor |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review